Jie Wang1, Jiancong Weng1, Hao Li1, Yuming Jiao1, Weilun Fu1, Ran Huo1, Zihan Yan1, Hongyuan Xu1, Jiong Zhan2, Shuo Wang1, Xin Du3, Yong Cao4, Jizong Zhao1. 1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China. 2. Neuroscience Imaging Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China. 3. Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No.2 Beijing Anzhen Road Chaoyang, District, Beijing 100029, China. 4. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119 South Fourth Ring Road West, Fengtai District, Beijing, 100071, China.
Abstract
BACKGROUND AND AIMS: The role of statins in unruptured intracranial aneurysm (UIA) growth and rupture remains ambiguous. This study sought to determine whether atorvastatin is associated with aneurysm growth and rupture in patients harboring UIA <7 mm. METHODS: This prospective, multicenter cohort study consecutively enrolled patients with concurrent UIA <7 mm and ischemic cerebrovascular disease from four hospitals between 2016 and 2019. Baseline and follow-up patient information was recorded. Because of the strong anti-inflammatory effect of aspirin, patients using aspirin were excluded. Patients taking atorvastatin 20 mg daily were atorvastatin users. The primary and exploratory endpoints were aneurysm rupture and growth, respectively. RESULTS: Among the 1087 enrolled patients, 489 (45.0%) took atorvastatin, and 598 (55%) took no atorvastatin. After a mean follow-up duration of 33.0 ± 12.5 months, six (1.2%) and five (0.8%) aneurysms ruptured in atorvastatin and non-atorvastatin groups, respectively. In the adjusted multivariate Cox analysis, UIA sized 5 to <7 mm, current smoker, and uncontrolled hypertension were associated with aneurysm rupture, whereas atorvastatin [adjusted hazard ratio (HR) 1.495, 95% confidence interval (CI) 0.417-5.356, p = 0.537] was not. Of 159 patients who had follow-up imaging, 34 (21.4%) took atorvastatin and 125 (78.6%) took no atorvastatin. Aneurysm growth occurred in five (14.7%) and 21 (16.8%) patients in atorvastatin and non-atorvastatin groups (mean follow-up: 20.2 ± 12.9 months), respectively. In the adjusted multivariate Cox analysis, UIAs sized 5 to <7 mm and uncontrolled hypertension were associated with a high growth rate; atorvastatin (adjusted HR 0.151, 95% CI 0.031-0.729, p = 0.019) was associated with a reduced growth rate. CONCLUSIONS: We conclude atorvastatin use is associated with a reduced risk of UIA growth, whereas atorvastatin is not associated with UIA rupture.The trial registry name:: The Clinic Benefit and Risk of Oral Aspirin for Unruptured Intracranial Aneurysm Combined With Cerebral IschemiaClinical Trial Registration-URL:: http://www.clinicaltrials.gov Unique identifier:: NCT02846259.
BACKGROUND AND AIMS: The role of statins in unruptured intracranial aneurysm (UIA) growth and rupture remains ambiguous. This study sought to determine whether atorvastatin is associated with aneurysm growth and rupture in patients harboring UIA <7 mm. METHODS: This prospective, multicenter cohort study consecutively enrolled patients with concurrent UIA <7 mm and ischemic cerebrovascular disease from four hospitals between 2016 and 2019. Baseline and follow-up patient information was recorded. Because of the strong anti-inflammatory effect of aspirin, patients using aspirin were excluded. Patients taking atorvastatin 20 mg daily were atorvastatin users. The primary and exploratory endpoints were aneurysm rupture and growth, respectively. RESULTS: Among the 1087 enrolled patients, 489 (45.0%) took atorvastatin, and 598 (55%) took no atorvastatin. After a mean follow-up duration of 33.0 ± 12.5 months, six (1.2%) and five (0.8%) aneurysms ruptured in atorvastatin and non-atorvastatin groups, respectively. In the adjusted multivariate Cox analysis, UIA sized 5 to <7 mm, current smoker, and uncontrolled hypertension were associated with aneurysm rupture, whereas atorvastatin [adjusted hazard ratio (HR) 1.495, 95% confidence interval (CI) 0.417-5.356, p = 0.537] was not. Of 159 patients who had follow-up imaging, 34 (21.4%) took atorvastatin and 125 (78.6%) took no atorvastatin. Aneurysm growth occurred in five (14.7%) and 21 (16.8%) patients in atorvastatin and non-atorvastatin groups (mean follow-up: 20.2 ± 12.9 months), respectively. In the adjusted multivariate Cox analysis, UIAs sized 5 to <7 mm and uncontrolled hypertension were associated with a high growth rate; atorvastatin (adjusted HR 0.151, 95% CI 0.031-0.729, p = 0.019) was associated with a reduced growth rate. CONCLUSIONS: We conclude atorvastatin use is associated with a reduced risk of UIA growth, whereas atorvastatin is not associated with UIA rupture.The trial registry name:: The Clinic Benefit and Risk of Oral Aspirin for Unruptured Intracranial Aneurysm Combined With Cerebral IschemiaClinical Trial Registration-URL:: http://www.clinicaltrials.gov Unique identifier:: NCT02846259.
Authors: Kimon Bekelis; Jeremy Smith; Weiping Zhou; Todd A MacKenzie; David W Roberts; Jonathan Skinner; Nancy E Morden Journal: Int J Stroke Date: 2015-06-29 Impact factor: 5.266
Authors: J Pablo Villablanca; Gary R Duckwiler; Reza Jahan; Satoshi Tateshima; Neil A Martin; John Frazee; Nestor R Gonzalez; James Sayre; Fernando V Vinuela Journal: Radiology Date: 2013-07-02 Impact factor: 11.105
Authors: B Gregory Thompson; Robert D Brown; Sepideh Amin-Hanjani; Joseph P Broderick; Kevin M Cockroft; E Sander Connolly; Gary R Duckwiler; Catherine C Harris; Virginia J Howard; S Claiborne Clay Johnston; Philip M Meyers; Andrew Molyneux; Christopher S Ogilvy; Andrew J Ringer; James Torner Journal: Stroke Date: 2015-06-18 Impact factor: 7.914
Authors: Felix J V Schlösser; Marco J D Tangelder; Hence J M Verhagen; Geert J M G van der Heijden; Bart E Muhs; Yolanda van der Graaf; Frans L Moll Journal: J Vasc Surg Date: 2008-04-28 Impact factor: 4.268
Authors: Ajay Malhotra; Xiao Wu; Howard P Forman; Holly K Grossetta Nardini; Charles C Matouk; Dheeraj Gandhi; Christopher Moore; Pina Sanelli Journal: Ann Intern Med Date: 2017-06-06 Impact factor: 25.391